Lipid N2-3L

Lipid N2-3L is a novel ionizable lipid used in combination with other lipids, such as L-PGTA also provided by Nucleosyn, in the formulation of original LNPs to elaborate new high-performances mRNA cancer vaccines. In the case of supramolecular lipid nanoparticles (SMLNPs) formulation, it has been shown that Lipid N2-3L enhanced the translation efficiency of mRNA. In the presence of β-cyclodextrin, the R848 adjuvant could also be encapsulated in an mRNA vaccine thanks to non-covalent host-guest complexation promoting dendritic cell maturation and antigen presentation after vaccination. It led thus to high in vivo antitumor efficacy boosted by a synergy with immune checkpoint blockade by potentiating the anticancer capability of cytotoxic T lymphocytes infiltrated in tumor sites.

Nucleosyn provides high-quality synthetic lipids for R&D use only.